OpenBilldrug price receipt

NADAC week of 2026-10-14

REYVOW 50 MG TABLET

FDA nonproprietary name: lasmiditan

For 30 tablets

Pharmacies pay

$2,660.92 filed

30 × $88.69728 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-05-20 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$2,736.03 filed

30 × $91.20098 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

1.0× estimated

Medicare paid about what pharmacies pay.

Part D averages every strength and form sold under “Reyvow” / “Lasmiditan Succinate” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-05-20 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$3,065.06 estimated

$2,660.92 + $399.14 (15%) + $5.00 fee per fill = $3,065.06

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-05-20 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

REYVOW 50 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as lasmiditan, under the trade name “Reyvow”.

FDA gives its dosage form as tablet and its route as oral.

The labeler, the company named on the label, is Eli Lilly and Company.

FDA lists no Established Pharmacologic Class for it.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00002-4312-08.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $2,660.92 for 30 tablets (30 × $88.69728 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-05-20. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 4, carried forward from the previous file.

This NDC’s NADAC was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: it took effect on 2026-05-20. The file is new; the price is not.

The NDC

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name lasmiditan with REYVOW 50 MG TABLET.

ProductPharmacies pay per unitMedicare per unit
REYVOW 50 MG TABLET this page
brand · tablet
$88.69728 per EA filed
eff. 2026-05-20
$91.20098 per EA filed
Part D 2024 average
REYVOW 100 MG TABLET
brand · tablet
$88.77148 per EA filed
eff. 2026-05-20
$91.20098 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-05-20 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

What Medicare paid

Medicare Part D paid $2,736.03 for 30 tablets, at an average of $91.20098 per EA in 2024 (2024-01-01 to 2024-12-31) for “Reyvow” and “Lasmiditan Succinate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 11,829 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for REYVOW 50 MG TABLET labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Reyvow / Lasmiditan Succinate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.